Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 4/20 | 0.42 |
| ▸ | FNTB | P49356 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 3/20 | 0.39 |
| ▸ | KRAS | P01116 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411026 | 0.88 | USP30 (0.40) | FNTAFNTBESR2KRASUSP30 | |
| SCHEMBL4409890 | 0.87 | MTNR1A (0.44) | RIPK1STS | |
| SCHEMBL4407499 | 0.86 | MAPT (0.41) | ESR2STSKRAS | |
| SCHEMBL4406512 | 0.85 | USP30 (0.49) | USP30 | |
| SCHEMBL4407107 | 0.85 | MAPK1 (0.44) | ESR2KRASUSP30 | |
| SCHEMBL23512794 | 0.84 | KRAS (0.39) | MEN1KMT2AESR2KRASUSP30 | |
| SCHEMBL29693098 | 0.84 | KRAS (0.39) | MEN1KMT2AESR2KRASUSP30 | |
| SCHEMBL4418597 | 0.84 | RIPK1 (0.44) | RIPK1KRAS | |
| SCHEMBL4410030 | 0.84 | LMNA (0.39) | RIPK1ESR2KRASUSP30 | |
| SCHEMBL4406534 | 0.82 | ESR2 (0.40) | RIPK1KMT2AESR2KRASUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | RIPK1 2672/4885MEN1 1646/4885KMT2A 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.